The EPS miss and declining net income are negative for the standalone stock, but the announced EQT takeover at a premium likely overhangs the price. Monitor regulatory approvals and shareholder vote for the takeover, expected to close mid-2027. The earnings miss may reduce the likelihood of a competing bid.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 6 $50.33entry
- T+1 · 8d ago +0.44%α −1.93% · $50.55
- T+5 · 4d ago −0.87%α −3.47% · $49.89
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
QIAGEN reported Q3 2026 net sales of $547.9M (+3% YoY) and GAAP diluted EPS of $0.51, below the consensus estimate of $0.63. Net income declined to $105.7M from $130.0M a year ago, pressured by higher restructuring costs and a normalized tax rate. The filing also discloses a subsequent event: a public takeover offer by EQT Private Equity at EUR 46.50 per share, valuing the company at approximately EUR 10.8 billion enterprise value.
Key Financial Metrics
Key Facts
- Q3 2026 net sales $547.9M, up 3% YoY from $532.6M
- GAAP diluted EPS $0.51, down from $0.60 YoY; consensus was $0.63
- Net income $105.7M vs $130.0M in Q3 2025, a 19% decline
- Gross margin improved to 64.6% from 62.2% YoY, benefiting from Parse acquisition and tariff refunds
- Operating income margin stable at 24.2% vs 24.3% YoY
- Restructuring, acquisition, integration and other costs surged to $19.2M from $8.1M YoY
- Effective tax rate normalized to 20.1% from 3.5% in Q3 2025 (which benefited from a worthless stock deduction)
- On October 21, 2026, QIAGEN announced a public takeover offer by EQT Private Equity at EUR 46.50 per share, valuing the company at approximately EUR 10.8 billion enterprise value
- Sample technologies grew 10% YoY; PCR/nucleic acid amplification declined 5%; Genomics/NGS grew 8%
- Cash and cash equivalents $805.1M, down from $839.0M at year-end 2025
Financial Impact
EPS miss of $0.12 vs consensus ($0.51 actual vs $0.63 estimate), net income down 19% YoY; restructuring charges $19.2M in Q3
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Sample technologies | $187.4M | +10.2% |
| Diagnostic solutions | $209.4M | +0.4% |
| PCR/Nucleic acid amplification | $71.2M | -5.4% |
| Genomics/NGS | $66.0M | +8.5% |
| Other | $13.8M | -21.9% |
Risk Factors
- Takeover may not complete due to regulatory hurdles or insufficient shareholder acceptance
- If deal fails, stock could re-rate lower given the earnings miss and elevated restructuring costs
- Patent litigation from Parse acquisition could result in additional damages up to $9.8M
- Restructuring costs expected to continue through 2026, pressuring margins
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001015820-26-000063 |
| Document: a2026q3form6-k.htm | 0001015820-26-000063 |
| Document: 0001015820-26-000063-index-headers.html | 0001015820-26-000063 |
| Document: 0001015820-26-000063-index.html | 0001015820-26-000063 |
| Document: 0001015820-26-000063.txt | 0001015820-26-000063 |
| Earnings Context (Synthetic; results releases only) | 0001015820-26-000063 |
Track record
7 reports on QGEN
2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +0.99% at T+5 after the Oct 27, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $50.33 to $49.89 Now $49.81 −1.03% ▼ −0.87% −3.47% vs SPY
- Nov 5, 202611d ago 6-K Bearish 6/10 Viewing Entry $50.33 to $49.89 Now $49.81 +1.03% ▲ +0.87% +3.47% vs SPY
- Nov 5, 202611d ago 6-K Neutral 5/10 No price data
- Nov 4, 202612d ago Institutional Cluster Mixed 3/10 Entry $50.86 to $50.10 Now $49.81 −2.06% ▼ −1.49% −4.78% vs SPY
- Oct 27, 202620d ago SC TO-C Bullish 7/10 Entry $50.33 to $50.83 Now $49.81 −1.03% ▲ +0.99% +1.71% vs SPY
- Oct 23, 202624d ago 6-K Bullish 8/10 Entry $50.39 to $50.22 Now $49.81 −1.15% ▼ −0.34% +0.22% vs SPY
- Oct 22, 202625d ago SC TO-C Bullish 8/10 Entry $50.22 to $50.34 Now $49.81 −0.82% ▲ +0.24% −0.47% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers